NCT02182323已完成1 期
Safety, Tolerance, and Pharmacokinetics of Single Oral Doses of 4 mg, 16 mg, 48 mg, 120 mg, 240 mg, 480 mg, 800 mg, and 1200 mg BI 201335 NA (PEG 400/TRIS/Meglumine/Water Solution) in Healthy Male Subjects, in a Randomised Single Blind, Placebo Controlled Rising Dose Study, Followed With an Open-label Intra-subject Two-stage Crossover Pilot Bioavailability Comparison of 480 mg BI 201335 NA in a PEG 400/TRIS/Meglumine/Water Solution Coadministered With Food
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 74
- 主要终点
- Number of patients with adverse events
研究概览
简要总结
The objective of this study was to investigate the safety, tolerability, and pharmacokinetics of BI 201335 NA following administration of single rising doses from 4 mg to 1200 mg. In addition, the food effect on the bioavailability of BI 201335 NA (480 mg) was investigated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy males according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead ECG (electrocardiogram), clinical laboratory tests
- •Age ≥18 and Age ≤50 years
- •BMI ≥18.5 and BMI ≤29.9 kg/m2 (Body Mass Index)
- •Signed and dated written informed consent prior to admission to the study in accordance with GCP (Good Clinical Practice) and the local legislation
排除标准
- •Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance
- •Any evidence of a clinically relevant concomitant disease
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Prior history of jaundice
- •Surgery of the gastrointestinal tract (except appendectomy)
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- •History of relevant orthostatic hypotension, fainting spells or blackouts
- •Chronic or relevant acute infections
- •History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)
- •Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
- •Use of drugs which might reasonably influence the results of the trial or that prolong the QT/QTc interval based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
- •Participation in another trial with an investigational drug within two months prior to administration or during the trial
- •Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
- •Inability to refrain from smoking alcohol and on trial days
- •Alcohol abuse (more than 60 g/day)
- •Drug abuse
- •Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
- •Excessive physical activities (within one week prior to administration or during the trial)
- •Any laboratory value outside the reference range that is of clinical relevance
- •Inability to comply with dietary regimen of trial site
- •A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 ms)
- •A history of additional risk factors for TdP (torsade de pointes) (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
研究组 & 干预措施
BI 201335 in single rising doses
Experimental
干预措施: BI 201335 NA (Drug)
Placebo
Placebo Comparator
干预措施: Placebo solution (Drug)
BI 201335 NA fasted or fed
Experimental
two randomized sequences:
- BI 201335 NA or placebo fasted
- BI 201335 NA or placebo after high-fat breakfast
干预措施: BI 201335 NA (Drug)
BI 201335 NA fasted or fed
Experimental
two randomized sequences:
- BI 201335 NA or placebo fasted
- BI 201335 NA or placebo after high-fat breakfast
干预措施: Placebo solution (Drug)
结局指标
主要结局
Number of patients with adverse events
时间窗: up to 12 days
Number of patients with abnormal findings in 12-lead ECG (electrocardiogram)
时间窗: up to 12 days
Number of patients with abnormal changes in laboratory tests (haematology, clinical chemistry and urinalysis)
时间窗: up to 12 days
Number of patients with abnormal findings in physical examination
时间窗: up to 12 days
Number of patients with clinically significant changes in vital signs (blood pressure, pulse rate)
时间窗: up to 12 days
Assessment of tolerability by investigator on a 4-point scale
时间窗: within 7 days after last trial procedure
次要结局
- tmax (time from dosing to maximum concentration)(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours post-dose)
- AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours post-dose)
- λz (terminal elimination rate constant in plasma)(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours post-dose)
- t1/2 (terminal half-life of the analyte in plasma)(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours post-dose)
- Cmax (maximum concentration of the analyte in plasma)(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours post-dose)
- AUC0-infinity (area under the concentration time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours post-dose)
- CL/F (apparent clearance of the analyte in the plasma after oral administration)(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours post-dose)
- CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2)(Pre-dose and 0-4, 4-12, 12-24, 24-48 hours post-dose in the single rising dose phase)
- MRTpo (Mean residence time of the analyte in the body after oral administration)(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours post-dose)
- Vz/F (apparent volume of distribution during the terminal phase λz following an oral dose)(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours post-dose)
- Aet1-t2 (amount of analyte that is eliminated in urine from the time point t1 to time point t2)(Pre-dose and 0-4, 4-12, 12-24, 24-48 hours post-dose in the single rising dose phase)
- fet1-t2 (fraction of analyte eliminated in urine from time point t1 to time point t2)(Pre-dose and 0-4, 4-12, 12-24, 24-48 hours post-dose in the single rising dose phase)
研究者
相似试验
终止
1 期
Single Rising Dose Study of BI 201335 ZW in Healthy Male SubjectsHealthyNCT02182271Boehringer Ingelheim8
已完成
1 期
First in Man Trial of BI 113608HealthyNCT01540825Boehringer Ingelheim80
终止
1 期
A Study in Healthy Japanese Men to Test How Different Doses of BI 894416 Are ToleratedHealthyNCT04540874Boehringer Ingelheim8
已完成
1 期
This Study in Healthy Men Tests How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Looks at How Food Influences the Amount of BI 1358894 in the BloodHealthyNCT03210272Boehringer Ingelheim83
已完成
1 期
A Study in Healthy Chinese People to Test How Different Doses of BI 1015550 Are Taken up in the BodyHealthyNCT05633862Boehringer Ingelheim24